Cost-effectiveness data use in promotions to be discussed at FDA March pharmacoeconomics meeting.
Executive Summary
COST-EFFECTIVENESS DATA IN PROMOTIONS: FDA MARCH 23-24 CONFERENCE will feature a panel on cost-effectiveness data as a marketing tool as part of a full two-day agenda. Battelle Center for Public Health Research & Evaluation Director Bryan Luce, PhD, and FDA Division of Drug Marketing, Advertising and Communications Director Lucy Rose will appear on the panel, "Comparing Treatment: Safety, Effectiveness and Cost-Effectiveness." The FDA-sponsored meeting is to be held at the National Institutes of Health's Masur Auditorium ("The Pink Sheet" Jan. 23, In Brief).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth